← Leaderboards
Kevin Shee
Dartmouth College
$176,288
Attributed
$176,288
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $50K · FY2017–20$100K$75K$50K$25K$0
'17
'18
'19
'20
Funding mix
By agency
NIH$176,288 · 1
By mechanism
F30$176,288 · 1
Top collaborators
No co-investigators on record.
Most similar at Dartmouth College
Same institution · by research overlap
- Steven Fiering$14,075,746
- Anne Gatewood Hoen$3,759,005
- Riley A Hampsch$72,279
- Nicole A. Ho$91,556
- Michael J Spinella$5,049,054
Others in their field
Other Emerging Leaders on “Combined Modality Therapy”
- Barbara Burtness · Yale University$11,235,253
- Jurgen Bernd Bulitta · State University Of New York At Buffalo$7,090,719
- Kathleen N. Moore · University Of Oklahoma$6,686,608
- Nilu Goonetilleke · Univ Of North Carolina Chapel Hill$6,073,977
- Feixiong Cheng · Cleveland Clinic Lerner Com-Cwru$5,834,007
- Nader Fotouhi · Global Alliance For Tb Drug Development$5,472,466
Research focus
Combined Modality Therapy1-Phosphatidylinositol 3-KinaseCombatAdipocytesAdjuvantApoptosisAdvanced DiseaseBioinformaticsAntibodiesBoneBreastBreast AdenocarcinomaBreast Cancer CellBreast Cancer Cell LineBreast Cancer ModelAromatase InhibitorsCancer RecurrenceCell Cycle ArrestCell LineCellsCellular StructuresClinical ManagementClinical TrialsCytokine
Grant awards (4)
Microenvironmental FGF2-mediated resistance to anti-estrogen and PI3K/mTOR pathway therapeutics in ER+ breast cancer$27,704
F30 · FY2020 · CA · contact PI
Microenvironmental FGF2-mediated resistance to anti-estrogen and PI3K/mTOR pathway therapeutics in ER+ breast cancer$50,016
F30 · FY2019 · CA · contact PI
Microenvironmental FGF2-mediated resistance to anti-estrogen and PI3K/mTOR pathway therapeutics in ER+ breast cancer$49,524
F30 · FY2018 · CA · contact PI
Microenvironmental FGF2-mediated resistance to anti-estrogen and PI3K/mTOR pathway therapeutics in ER+ breast cancer$49,044
F30 · FY2017 · CA · contact PI